Cue Biopharma Q3 2026: What's Behind the Wider-Than-Expected Loss
As seen on the 24/7 Wall St. homepage on November 16, 2026.
The loss came in at more than double consensus, missing expectations on non-cash charges including the Ascendant top-up share obligation revaluation and performance equity grants from the Q2 strategic overhaul. With collaboration revenue nearly gone as Boehringer Ingelheim activity winds down, $57.9 million in cash has to carry CUE-221 into food allergy trials after FDA IND clearance.
Continue ReadingShow less
Cue Biopharma reported a Q3 2026 GAAP loss of $4.74 per share, more than double the consensus estimate of $2.24. The gap was driven heavily by non-cash items, most notably a $3.4 million non-cash loss tied to the revaluation of the Ascendant top-up share obligation and significant stock-based compensation from performance-based equity grants issued after the company's Q2 2026 strategic overhaul.
Revenue fell to $132,000 from $2.15 million in the year-ago period, a decline of nearly 94%, as activity under the Boehringer Ingelheim collaboration and license agreement continued to wind down. That revenue line is now nearly empty, leaving Cue operating almost entirely on its cash balance of $57.9 million. The net loss widened to $50 million from $7.45 million a year earlier, though that comparison is similarly distorted by the one-time and non-cash charges.
The pipeline is where management is directing investor attention. CUE-221 cleared an FDA IND for food allergy, opening a new indication beyond the Phase 2 chronic spontaneous urticaria study that met its primary endpoint. The CSU data showed a dose-responsive, statistically significant rate of complete hives resolution, with the 4 mg/kg dose maintaining that benefit at week 28, twelve weeks after the last dose. Among patients with high baseline IgE of 300 IU/mL or above, 78% on the 4 mg/kg arm reached the primary endpoint at week 12 versus 0% on placebo.
Sponsored
CUE-401, a bispecific IL-2 and TGF-beta dual agonist designed for autoimmune disease, has entered a first-in-human Phase 1 trial with dosing underway in the first cohort. Meanwhile, an amended ImmunoScape license agreement is expected to bring in $5.5 million in payments: $3 million in Q4 2026, $1.5 million in Q3 2027, and $1 million in Q4 2027. Those inflows provide a modest offset to operating cash consumption as CUE-221 moves toward food allergy trials.
The core question for investors is whether $57.9 million in cash is sufficient runway to generate meaningful clinical readouts from both programs before additional financing is required. Management has acknowledged the need for additional capital, and the Ascendant top-up share obligation introduces further dilution risk. The heavy Q3 charges are largely non-recurring, but the underlying cost structure is rising on clinical trial start-up expenses, and collaboration revenue is no longer a meaningful buffer.
Mentioned: CUE